Global Organ Transplantation Demand Will Expand Market Opportunity

The notable rise in Hansa Biopharma’s consensus analyst price target to SEK90.00 is primarily driven by a substantial increase in its anticipated future P/E multiple, reflecting higher market growth expectations. What's in the News Hansa Biopharma announced topline results from three DMD patients treated with imlifidase prior to ELEVIDYS gene therapy, showing rapid IgG reduction and enabled gene therapy, but with lower micro-dystrophin expression than other trials; next steps to be discussed with Sarepta.

AnalystConsensusTarget has increased revenue growth from 90.1% to 99.4%, decreased profit margin from 16.7% to 12.0% and increased future PE multiple from 49.8x to 60.1x.

AnalystConsensusTarget has increased revenue growth from 80.3% to 90.1%.

AnalystConsensusTarget has decreased revenue growth from 91.8% to 80.3% and increased future PE multiple from 37.2x to 50.5x.